--- title: Sample Size and Power for Non-Parametric Analysis description: "Free Webinar: Uncover insights on survival analysis with power calculations, challenges, and innovative approaches, including non-proportional hazards." image: https://www.statsols.com/hubfs/Exploring%20Survival%20Analysis%20Designs%20for%20Clinical%20Trials-1.png --- [![nQuery Logo-White](https://www.statsols.com/hs-fs/hubfs/nQuery%20Logo-White.png?width=705&height=175&name=nQuery%20Logo-White.png "nQuery Logo-White")](https://www.statsols.com/) ** ** ![Sample size and power training for use in clinical trials](https://www.statsols.com/hs-fs/hubfs/Master_Images/___PageImages/Software_Training/Sample%20size%20and%20power%20training%20for%20use%20in%20clinical%20trials.jpeg?width=1000&name=Sample%20size%20and%20power%20training%20for%20use%20in%20clinical%20trials.jpeg "Sample size and power training for use in clinical trials") #### Webinar # **Exploring Survival Analysis Designs for Clinical Trials** ### **Identifying & Addressing Challenges With Survival Sample Size & Power** ### This webinar has ended Watch on Demand ** #### About the webinar Survival analysis is one of the most common statistical approaches used in clinical trials, especially in clinical areas such as oncology. However, it is also one of the most complex and flexible statistical areas with this increasing in recent years due to the emergence of innovative treatments such as immunotherapies. This complexity affects every part of trial design and analysis including power analysis and sample size determination. Join us for this free webinar as we explore the concept of survival analysis in clinical trials and examine some of the challenges that a researcher can face including accrual, dropout, follow-up type and non-proportional hazards. #### In this free webinar, you will learn about: ** More about the webinar   A key difference between clinical trials with survival endpoints and other endpoints (such as comparing means and proportions) is that in a survival analysis, the power is directly linked to the number of events and the researcher is recruiting the sample size they expect is required to achieve a target number of events.   In practical terms, this means there is significant flexibility required to deal with issues such as varying accrual, follow-up length, hazard rate and dropout patterns even within the “standard” two independent group log-rank scenario.   Another design issue to consider is whether all subjects should be followed for the same fixed period of time or if each subject should be observed until the end of the study once they are recruited.   These considerations will all impact both the total sample size or overall trial length required to achieve the target number of events.   In addition to this, the issue of non-proportional hazards (where the hazard ratio varies over time) has been of particular interest in recent years, especially in the context of immunotherapies which commonly have a “delayed effect”.   Multiple proposals have emerged for the analysis of these complex survival datasets such as weighted linear rank tests (e.g. Fleming-Harrington, Modestly Weighted) and the MaxCombo test.   In this free webinar, we delve into survival analysis within the context of clinical trials and scrutinize various challenges researchers may encounter.   ** #### Duration - 60 minutes **Speaker:** Paul Murphy, Research Statistician, nQuery ### Watch Now All info submitted is secure. View our [privacy policy](https://www.statsols.com/privacy-policy). ** About Our Host ****Paul Murphy** ![Paul-Murphy-nQuery-Researcher-1](https://www.statsols.com/hs-fs/hubfs/Staff_Photos/Headshots/Paul-Murphy-nQuery-Researcher-1.png?width=150&height=150&name=Paul-Murphy-nQuery-Researcher-1.png)   #### nQuery Research Statistician **Reducing the risk & cost of clinical trials, for innovative organizations such as:** ![Sanofi-updated-grey](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Sanofi-updated-grey.jpg?width=80&name=Sanofi-updated-grey.jpg "Sanofi-updated-grey") ![worldwide-clinical-trials](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/worldwide-clinical-trials.jpg?width=300&name=worldwide-clinical-trials.jpg "worldwide-clinical-trials") ![Covance-G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Covance-G_Logo.jpg?width=354&name=Covance-G_Logo.jpg "Covance-G_Logo") ![quintiles_logo_2017_grey](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/quintiles_logo_2017_grey.jpg?width=300&name=quintiles_logo_2017_grey.jpg "quintiles_logo_2017_grey") ![FDA_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/FDA_G_Logo.jpg?width=60&name=FDA_G_Logo.jpg "FDA_G_Logo") ![AstellasG_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/AstellasG_Logo.jpg?width=291&name=AstellasG_Logo.jpg "AstellasG_Logo") ![celgene_logo_download](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/celgene_logo_download.jpg?width=91&name=celgene_logo_download.jpg "celgene_logo_download") ![Boehringer_Ingelheim_Logo-png-updated](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Boehringer_Ingelheim_Logo-png-updated.jpg?width=300&name=Boehringer_Ingelheim_Logo-png-updated.jpg "Boehringer_Ingelheim_Logo-png-updated") ![PRA_Health_Sciences](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/PRA_Health_Sciences.jpg?width=68&name=PRA_Health_Sciences.jpg "PRA_Health_Sciences") ![Astrazeneca logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Astrazeneca%20logo.png?width=322&name=Astrazeneca%20logo.png "Astrazeneca logo") ![Amgen_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Amgen_G_Logo.jpg?width=350&name=Amgen_G_Logo.jpg "Amgen_G_Logo") ![Novartis_G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Novartis_G_Logo.jpg?width=508&name=Novartis_G_Logo.jpg "Novartis_G_Logo") ![abbvie-logo-updated_tmp15240](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/abbvie-logo-updated_tmp15240.jpg?width=365&name=abbvie-logo-updated_tmp15240.jpg "abbvie-logo-updated_tmp15240") ![Merck_GLogo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Merck_GLogo.jpg?width=310&name=Merck_GLogo.jpg "Merck_GLogo") ![Biogen-updated-logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Biogen-updated-logo.jpg?width=258&name=Biogen-updated-logo.jpg "Biogen-updated-logo") ![Ipsen-logo-only](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Ipsen-logo-only.jpg?width=300&name=Ipsen-logo-only.jpg "Ipsen-logo-only") ![Eli_Lilly_and_Company-G_Logo](https://www.statsols.com/hs-fs/hubfs/Master_Images/Client_Logos/Greyscale%20Logos%202018-2019/Eli_Lilly_and_Company-G_Logo.jpg?width=120&name=Eli_Lilly_and_Company-G_Logo.jpg "Eli_Lilly_and_Company-G_Logo") ###### Is there someone in your network that would be interested in our webinar? Share this page by clicking below. [![Share on linkedin](https://7528302.fs1.hubspotusercontent-na1.net/hub/7528302/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/linkedin-color.png?width=24&name=linkedin-color.png) ](http://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fidentifying-and-addressing-challenges-with-survival-sample-size-and-power%3Futm_medium%3Dsocial%26utm_source%3Dlinkedin) [![Share on twitter](https://7528304.fs1.hubspotusercontent-na1.net/hub/7528304/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/twitter-color.png?width=24&name=twitter-color.png) ](https://twitter.com/intent/tweet?original_referer=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fidentifying-and-addressing-challenges-with-survival-sample-size-and-power%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&url=https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fidentifying-and-addressing-challenges-with-survival-sample-size-and-power%3Futm_medium%3Dsocial%26utm_source%3Dtwitter&source=tweetbutton&text=) [![Share on email](https://7528311.fs1.hubspotusercontent-na1.net/hub/7528311/hubfs/raw_assets/public/mV0_d-web-default-modules_hubspot/img/email-color.png?width=24&name=email-color.png) ](mailto:?subject=Check%20out%20https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fidentifying-and-addressing-challenges-with-survival-sample-size-and-power%3Futm_medium%3Dsocial%26utm_source%3Demail%20&body=Check%20out%20https%3A%2F%2Fwww.statsols.com%2Fwebinar%2Fidentifying-and-addressing-challenges-with-survival-sample-size-and-power%3Futm_medium%3Dsocial%26utm_source%3Demail)